Abstract: One of the main problems with introducing target therapeutics and diagnostic biomarkers (Target substances) into the brain is the nearly impenetrable blood brain barrier. Some of the proposed described solutions to mobilizing these target therapeutics and markers into select areas of the brain include nano-particles and nano-capsules containing at least one of the target substances with exposed cannabinoid functional end groups that can selectively facilitate nano-capsule traversal across the blood brain barrier into brain tissue. In this way, the target substances can reach their intended target within the brain to either treat or identify regions of pathology. Certain concepts described involve nano/micro-particles with exposed cannabinoid functional end groups extending beyond the surface of the nano-particles.

Abstract: The invention refers to an oral pharmaceutical tableted dosage form which comprises a mixture of: a) granules comprising ferrimannitol-ovalbumin (FMOA) and at least an intragranular pharmaceutical acceptable excipient including a binder; and b) extragranular pharmaceutical excipients including a filler and a binder; which may be obtained by wet-granulation and compression.

Abstract: The invention refers to an oral pharmaceutical tableted dosage form which comprises a mixture of: a) granules comprising ferrimannitol-ovalbumin (FMOA) and at least an intragranular pharmaceutical acceptable excipient including a binder; and b) extragranular pharmaceutical excipients including a filler and a binder; which may be obtained by wet-granulation and compression.